Delivery of EZH2-shRNA with mPEG-PEI nanoparticles for the treatment of prostate cancer in vitro

Wu,Yinxia; Yu,Junjie; Liu,Yongbiao; Yuan,Lin; Yan,Hang; Jing,Jing; Xu,Guoping

doi:10.3892/ijmm.2014.1724

Delivery of EZH2-shRNA with mPEG-PEI nanoparticles for the treatment of prostate cancer in vitro

Authors:
- Yinxia Wu
- Junjie Yu
- Yongbiao Liu
- Lin Yuan
- Hang Yan
- Jing Jing
- Guoping Xu
View Affiliations

Affiliations: Department of Oncology, Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu 225001, P.R. China, Department of Urology, Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu 225001, P.R. China, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: April 4, 2014 https://doi.org/10.3892/ijmm.2014.1724
Pages: 1563-1569

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Small interfering RNA (siRNA) is a promising therapeutic approach for castration-resistant prostate cancer (PCa). For the clinical application of siRNA, it is vital to find a safe and efficient gene transfer vector. Nanotechnology can provide a crucial advantage in developing strategies for cancer management and treatment by helping to improve the safety and efficacy of new therapeutic delivery vehicles. In this study, we describe a novel nanoparticle (mPEG-PEI) as an efficient non-viral carrier and found that this copolymer displayed enhanced efficiency in the shRNA-mediated knockdown of target genes. The enhancer of zeste homolog 2 (EZH2) is often elevated in castration-resistant PCa and has been implicated in the progression of human PCa. Targeting EZH2 may have therapeutic efficacy for the treatment of metastatic, hormone-refractory PCa. mPEG-PEI binds plasmid DNA yielding nanoparticles and these complexes exhibit low cytotoxicity and high gene transfection efficiency. Taken together, mPEG-PEI may be a promising non-viral gene carrier for the delivery of EZH2 short hairpin (sh)RNA to PC3 cells for advanced PCa therapy.

View Figures

View References

1	Cavalli G: Molecular biology. EZH2 goes solo. Science. 338:1430–1431. 2012. View Article : Google Scholar : PubMed/NCBI
2	Cao Q, Mani RS, Ateeq B, et al: Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell. 20:187–199. 2011. View Article : Google Scholar : PubMed/NCBI
3	van Leenders GJ, Dukers D, Hessels D, et al: Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol. 52:455–463. 2007.PubMed/NCBI
4	Ren G, Baritaki S, Marathe H, et al: Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res. 72:3091–3104. 2012. View Article : Google Scholar : PubMed/NCBI
5	Karanikolas BD, Figueiredo ML and Wu L: Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol Cancer Res. 7:1456–1465. 2009. View Article : Google Scholar : PubMed/NCBI
6	Varambally S, Dhanasekaran SM, Zhou M, et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 419:624–629. 2002. View Article : Google Scholar : PubMed/NCBI
7	Bohrer LR, Chen S, Hallstrom TC and Huang H: Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer. Endocrinology. 151:5136–5145. 2010. View Article : Google Scholar : PubMed/NCBI
8	Xu K, Wu ZJ, Groner AC, et al: EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science. 338:1465–1469. 2012. View Article : Google Scholar : PubMed/NCBI
9	Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G and Sood AK: RNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 11:59–67. 2011. View Article : Google Scholar : PubMed/NCBI
10	Park TG, Jeong JH and Kim SW: Current status of polymeric gene delivery systems. Adv Drug Deliv Rev. 58:467–486. 2006. View Article : Google Scholar : PubMed/NCBI
11	Jing GJ, Fu ZG, Dan B, Lin LR, Yang TC and Shi SL: Development and evaluation of a novel nano-scale vector for siRNA. J Cell Biochem. 111:881–888. 2010. View Article : Google Scholar : PubMed/NCBI
12	Wang Z, Liu G, Zheng H and Chen X: Rigid nanoparticle-based delivery of anti-cancer siRNA: Challenges and opportunities. Biotechnol Adv. Sep 5;S0734-9750(13)00154-7. 2013.(Epub ahead of print).
13	Mintzer MA and Simanek EE: Nonviral vectors for gene delivery. Chem Rev. 109:259–302. 2009. View Article : Google Scholar : PubMed/NCBI
14	Huang W, Lv M and Gao Z: Polyethylenimine grafted with diblock copolymers of polyethylene glycol and polycaprolactone as siRNA delivery vector. J Control Release. 152(Suppl 1): e143–e145. 2011. View Article : Google Scholar : PubMed/NCBI
15	Weber ND, Merkel OM, Kissel T and Muñoz-Fernández MA: PEGylated poly(ethylene imine) copolymer-delivered siRNA inhibits HIV replication in vitro. J Control Release. 157:55–63. 2012.PubMed/NCBI
16	Xu Z, Jin J, Siu LK, et al: Folic acid conjugated mPEG-PEI600 as an efficient non-viral vector for targeted nucleic acid delivery. Int J Pharm. 426:182–192. 2012. View Article : Google Scholar : PubMed/NCBI
17	Veiseh O, Kievit FM, Mok H, et al: Cell transcytosing poly-arginine coated magnetic nanovector for safe and effective siRNA delivery. Biomaterials. 32:5717–5725. 2011. View Article : Google Scholar : PubMed/NCBI
18	Shi S, Zhu X, Guo Q, et al: Self-assembled mPEG-PCL-g-PEI micelles for simultaneous codelivery of chemotherapeutic drugs and DNA: synthesis and characterization in vitro. Int J Nanomedicine. 7:1749–1759. 2012.PubMed/NCBI
19	Liu Y, Liu Z, Wang Y, et al: Investigation of the performance of PEG-PEI/ROCK-II-siRNA complexes for Alzheimer’s disease in vitro. Brain Res. 1490:43–51. 2013.PubMed/NCBI
20	Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar
21	Kirby M, Hirst C and Crawford ED: Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 65:1180–1192. 2011. View Article : Google Scholar : PubMed/NCBI
22	Min J, Zaslavsky A, Fedele G, et al: An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med. 16:286–294. 2010. View Article : Google Scholar : PubMed/NCBI
23	Tan J, Yang X, Zhuang L, et al: Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21:1050–1063. 2007. View Article : Google Scholar : PubMed/NCBI
24	Cao R, Wang L, Wang H, et al: Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 298:1039–1043. 2002. View Article : Google Scholar : PubMed/NCBI
25	Yu J, Yu J, Rhodes DR, Tomlins SA, et al: A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 67:10657–10663. 2007. View Article : Google Scholar
26	Bryant RJ, Cross NA, Eaton CL, Hamdy FC and Cunliffe VT: EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate. 67:547–556. 2007. View Article : Google Scholar : PubMed/NCBI
27	Cao P, Deng Z, Wan M, et al: MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer. 9:1082010. View Article : Google Scholar : PubMed/NCBI
28	Takeshita F, Minakuchi Y, Nagahara S, et al: Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA. 102:12177–12182. 2005. View Article : Google Scholar : PubMed/NCBI
29	Monteagudo S, Pérez-Martínez FC, Pérez-Carrión MD, et al: Inhibition of p42 MAPK using a nonviral vector-delivered siRNA potentiates the anti-tumor effect of metformin in prostate cancer cells. Nanomedicine (Lond). 7:493–506. 2012. View Article : Google Scholar : PubMed/NCBI
30	Giger EV, Castagner B, Räikkönen J, Mönkkönen J and Leroux JC: siRNA transfection with calcium phosphate nanoparticles stabilized with PEGylated chelators. Adv Healthc Mater. 2:134–144. 2013. View Article : Google Scholar : PubMed/NCBI
31	Li YH, Shi QS, Du J, et al: Targeted delivery of biodegradable nanoparticles with ultrasound-targeted microbubble destruction-mediated hVEGF-siRNA transfection in human PC-3 cells in vitro. Int J Mol Med. 31:163–171. 2013.
32	Liu XQ, Xiong MH, Shu XT, Tang RZ and Wang J: Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth. Mol Pharm. 9:2863–2874. 2012. View Article : Google Scholar : PubMed/NCBI
33	Wang Y, Su J, Cai W, et al: Hepatocyte-targeting gene transfer mediated by galactosylated poly(ethylene glycol)-graft-polyethylenimine derivative. Drug Des Devel Ther. 7:211–221. 2013. View Article : Google Scholar : PubMed/NCBI
34	Wu Y, Wang W, Chen Y, et al: The investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitro. Int J Nanomedicine. 5:129–136. 2010. View Article : Google Scholar : PubMed/NCBI
35	Aigner A: Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo. J Biomed Biotechnol. 2006:716592006. View Article : Google Scholar : PubMed/NCBI
36	Liang B, He ML, Xiao ZP, et al: Synthesis and characterization of folate-PEG-grafted-hyperbranched-PEI for tumor-targeted gene delivery. Biochem Biophys Res Commun. 367:874–880. 2008. View Article : Google Scholar : PubMed/NCBI